Physician profile
Sakeena Fatima
NPI 1205332384
$2,225.43
in general payments reported to CMS, 2019-2025
26 companies · $702 in 2025
The $702 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.90 · 2022: $86.85 · 2023: $757 · 2024: $655 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $475.99 | 2023-2025 | |
| Incyte Corporation | $302.83 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $259.64 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $202.42 | 2022-2025 | |
| Janssen Biotech, INC. | $156.65 | 2023-2024 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $110.68 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $99.84 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $78.45 | 2023-2025 | Ilumya |
| Dermavant Sciences, INC. | $58.44 | 2023 | Vtama |
| Regeneron Healthcare Solutions, INC. | $56.74 | 2022-2023 | Dupixent |
| Arcutis Biotherapeutics, INC. | $54.73 | 2024-2025 | Zoryve |
| Ucb, INC. | $52.66 | 2023 | Bimzelx, Cimzia |
| Pfizer INC. | $46.49 | 2022-2024 | |
| Fresenius Kabi USA, LLC | $41.43 | 2023 | Idacio |
| Biofrontera INC. | $39.43 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $25.13 | 2025 | Ycanth |
| Celgene Corporation | $24.90 | 2019 | |
| Blueprint Medicines Corporation | $23.00 | 2022 | |
| Botanix Sb INC | $20.00 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.67 | 2025 | Cabtreo, Siliq, Jublia |
| Journey Medical Corporation | $17.51 | 2022 | |
| Leo Pharma INC. | $15.17 | 2023 | Adbry |
| Nobelpharma America, LLC | $14.76 | 2023 | |
| Amgen INC. | $14.00 | 2025 | Otezla |
| Genentech USA, INC. | $12.79 | 2023 | Erivedge |
| Organon LLC | $2.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sakeena Fatima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.